Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.
[1] It is a fully human pentameric IgM antibody with a mouse J chain.
[1] Panobacumab is being developed by Aridis Pharmaceuticals.
As of November 15th it is in phase 2 clinical trials.
You can help Wikipedia by expanding it.This monoclonal antibody–related article is a stub.